Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

More Web Proxy on the site http://driver.im/

X

Drug Profile

BB 1101

Latest Information Update: 15 Jan 2022

Price :

£46 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator British Biotech
Class Antirheumatics; Peptides
Mechanism of Action Metalloprotease inhibitors; Peptide hydrolase inhibitors; Tumour necrosis factor inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Encephalomyelitis; Rheumatic disorders

Most Recent Events

08 Nov 1996 Discontinued-Preclinical for Encephalomyelitis in United Kingdom (Unknown route)
08 Nov 1996 Discontinued-Preclinical for Rheumatic disorders in United Kingdom (Unknown route)
16 Feb 1996 New profile

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com